Dabrafenib Mesylate + Trametinib Dimethyl Sulfoxide + Uprosertib
Phase 1/2CompletedDevelopment Stage
Hematopoietic and Lymphoid Cell Neoplasm
Hematopoietic and Lymphoid Cell Neoplasm, Locally Advanced Malignant Solid Neoplasm, Locally Advanced Melanoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Unresectable Malignant Solid Neoplasm, Unresectable Melanoma
Oct 8, 2013 → Dec 23, 2023
About Dabrafenib Mesylate + Trametinib Dimethyl Sulfoxide + Uprosertib
Dabrafenib Mesylate + Trametinib Dimethyl Sulfoxide + Uprosertib is a phase 1/2 stage product being developed by Novartis for Hematopoietic and Lymphoid Cell Neoplasm. The current trial status is completed. This product is registered under clinical trial identifier NCT01902173. Target conditions include Hematopoietic and Lymphoid Cell Neoplasm, Locally Advanced Malignant Solid Neoplasm, Locally Advanced Melanoma.
Hype Score Breakdown
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01902173 | Phase 1/2 | Completed |
Competing Products
20 competing products in Hematopoietic and Lymphoid Cell Neoplasm